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Background: Disseminated tumor cells (DTCs) have potential to predict the effect of adjuvant treatment. The
purpose of this study was to compare two methods, reverse transcription quantitative PCR (RT-qPCR) and
immunocytochemisty (ICC), for detecting breast cancer DTCs in bone marrow (BM) from early breast cancer
patients.
Methods: We investigated a subset (n = 313) of BM samples obtained from 271 early breast cancer patients in
the “Secondary Adjuvant Taxotere Treatment” (SATT)-trial. All patients in this study had node positive or
intermediate/high-risk node negative non-metastatic disease. The DTCs were detected by ICC using AE1-AE3
anti-cytokeratin monoclonal antibodies. Patients with DTCs detected in their BM by ICC after standard adjuvant
fluorouracil, cyclophosphamide, epirubicin (FEC) chemotherapy were offered docetaxel treatment. For comparison,
5 × 106 mononuclear cells from the aliquoted BM samples were also analyzed by RT-qPCR using a multimarker
(MM) assay based on the tumor cell mRNA markers keratin 19 (KRT19), mammaglobin A (hMAM), and TWIST1. In the
MM-assay, a sample was defined as positive for DTCs if at least one of the mRNA markers was positive.
Results: The MM RT-qPCR assay identified DTCs in 124 (40%) of the 313 BM samples compared with 23/313 (7%)
of the samples analyzed by ICC. The concordance between the MM RT-qPCR and ICC was 61% (Kappa value = 0.04)
and twelve of the BM samples were positive by both methods. By RT-qPCR, 46/313 (15%) samples were positive
for KRT19, 97/313 (31%) for TWIST1, and 3/313 (1%) for hMAM mRNA. There were no statistically significant
associations between the individual mRNA markers.
Conclusion: The RT-qPCR based method demonstrated more DTC-positive samples than ICC. The relatively low
concordance of positive DTC-status between the two different assessment methods suggests that they may be
complementary. The clinical relevance of the methods will be evaluated based on future clinical outcome data.
Trial registration: ClinicalTrials.gov: NCT00248703.
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Despite a continuous effort to improve cancer diagnostics
and treatment, breast cancer remains a leading cause of
death among women worldwide. Current adjuvant treat-
ment decisions are dependent on well-known prognostic
factors including TNM-staging and histological grade, as
well as the estrogen receptor (ER), progesterone receptor
(PgR), human epidermal growth factor receptor 2 (HER2),
and more recently Ki-67-status [1]. The search for better
prognostic factors, as well as predictors of the effect of
adjuvant treatment, has led to a thorough evaluation of
disseminated tumor cells (DTCs) and their persistence in
bone marrow (BM) [2-5]. Moreover, DTCs have been
shown to provide independent prognostic information in
breast cancer patients [2-5]. However, more research is
needed before the implementation of BM status in routine
clinical practice. The predictive value of BM status as a
tool in making adjuvant treatment decisions has yet to be
investigated in randomized phase III trials. Furthermore,
the detection of tumor cells in the BM does not always
lead to disease relapse. Many patients with positive DTC
status do not relapse, and DTCs can be detected in pa-
tients with ductal carcinoma in situ [6]. The mechanisms
behind tumor dormancy and the possibility of tumor
cell re-awakening are poorly understood. Interestingly,
increasing evidence has emerged in the last few years
supporting that the addition of bisphosphonates in the
adjuvant treatment both reduces the risk of persistent
DTCs and improves survival [7-10]. This supports the
biological relevance of DTCs and the importance of
methods to accurately assess the DTC-status when
selecting patients for adjuvant treatment.
However, different methods are used to assess DTCs
in the BM, and there is a clear need for standardization.
Due to the very low frequency of DTCs in the BM, different
methods are used to enrich tumor cells in the BM samples
before detection. The enrichment can be based on density
gradient centrifugation, flow cytometry, immunomagnetic
beads, and membrane filtration [11]. Protocols based on
immunocytochemistry (ICC) and reverse transcription
quantitative PCR (RT-qPCR) are the most commonly
used methods for DTC detection. When ICC is used for
DTC detection, the results will be affected by the choice
of keratin antibodies, as discrepancies between different
antibody mixtures have been reported [11-13]. Similarly,
the choice of mRNA markers, as well as different assays
and platforms, affect the performance of RT-qPCR based
DTC detection [4,14-19]. Thus, the comparison of studies
based on different detection methods is challenging. Never-
theless, a few studies report the concordance between ICC-
based and RT-qPCR-based DTC detection in breast cancer
patients to be about 70-80% [20-22]; although, these num-
bers are primarily reflecting that the majority of patients
have negative BM-status with both methodologies.In the present study we compared a multimarker (MM)
RT-qPCR assay, consisting of keratin 19 (KRT19), TWIST1,
and mammaglobin A (hMAM), with ICC using the
AE1-AE3 mAb for the detection of DTCs in 267 early breast
cancer patients previously treated with adjuvant fluorouracil,
cyclophosphamide, epirubicin (FEC) chemotherapy.
Methods
Patients
A total of 1121 patients were prospectively recruited to
the “Secondary Adjuvant Taxotere Treatment” (SATT)
trial from October 2003 to May 2008 [23]. In total, 313
BM samples from 271 of these patients were selected for
the present study. All samples collected within a limited
timeframe during the SATT trial were included in our
study to avoid selection bias. Briefly, in the SATT-trial,
only breast cancer patients with node positive or high-risk
node negative disease (T1c/T2, GII-III, N0) were recruited.
BM aspirations were performed twice in all patients.
The first aspiration (BM1) was collected 8-12 weeks
after standard adjuvant chemotherapy (FEC); whereas,
a second BM aspiration was collected 6 months later
(BM2). BM2-samples were analyzed by ICC for the
presence of persisting DTCs after adjuvant chemotherapy.
Patients with positive BM2 samples were then treated with
6 cycles of docetaxel every 3 weeks and two additional BM
samples were collected from these patients approximately
1 month (BM3) and 13 months (BM4) after the last do-
cetaxel infusion. Of the 313 BM samples included in
our study, 92 were BM1, 187 were BM2, 14 were BM3,
and 18 were BM4. In only a few cases, the BM-samples
(BM1-4) were from the same patient, as all of our samples
were collected consecutively during a limited timeframe.
BM samples from 29 healthy women constituted the con-
trol group for the RT-qPCR analyses.
The SATT trial was approved by the Regional Committee
for Medical and Health Research Ethics (REC South-
East. Permit Number: S-03032) in compliance with the
Declaration of Helsinki, and written consent was obtained
from all patients. The study is registered in ClinicalTrials.
gov (registration number NCT00248703, registration date
November 3rd, 2005), and is reported according to the
recommendations for tumor marker prognostic studies
(REMARK) [24].
BM sampling and handling
The BM samples were collected and processed as pre-
viously described [5]. Briefly, using local anesthesia, a
small skin incision was first made to avoid contaminat-
ing epithelial cells before 5 ml of BM were aspirated
from both posterior iliac crests using a syringe prefilled
with 1 ml sodium-heparin. Mononuclear cells, including
DTCs, were enriched from the BM aspirates by density
centrifugation using Lymphoprep™ (Axis-Shield). The
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immediate preparation of cytospins (performed at Oslo
University Hospital) and mRNA isolation (performed
at Stavanger University Hospital). The remaining cells
were stored in liquid N2 for later use.
Immunocytochemistry
The cytospins were stained using the AE1-AE3 anti-
cytokeratin antibodies as previously described [5,25].
The detection of DTCs was done by automated microscopy
screening (Ariol SL50, Applied Imaging) or by manual
screening with a light microscope. All candidate positive
cells were reviewed by a pathologist (E.B.). Immunopo-
sitive cells were recorded according to recommended
guidelines [5,25-28].
RNA isolation and cDNA synthesis
Approximately 5 x 106 cells were collected for RNA isola-
tion. The mononuclear cell pellets were lysed in 350 μl
RLT-lysis buffer (Qiagen) before total RNA was extracted
using the RNeasy Mini Kit (Qiagen), according to the
manufacturer’s protocol. All RNA samples were treated in
a total volume of 10 μl with DNase I by incubating 1 μg
total RNA from each sample with 1 unit RQ1 RNAse-free
DNAse (Promega) in 1X First Strand Synthesis buffer
(Invitrogen) containing 10 units RNAseOUT RNAse in-
hibitor (Invitrogen). The reaction mixture was incubated
at 37°C for 30 min before the DNAse I was inactivated by
adding 1 μl RQ1 stop solution, followed by incubation for
10 min at 65°C. Complementary DNA was synthesized by
M-MLV reverse transcriptase in a total volume of 20 μl
according to the manufacturer’s protocol (Invitrogen).
Negative control samples without reverse transcriptase
were included during cDNA synthesis.
Real-time polymerase chain reaction assays
The amplification of KRT19 (GenBank Accession num-
ber NM_002276), hMAM (GenBank Accession number
U33147), and TWIST1 (GenBank Accession number
NM_000474) were performed as previously described,
with minor modifications for the hMAM assay [4,18,29].
The concentration of the primers were reduced from 0.8 to
0.3 μM, and the amount of cDNA template increased
to 50 ng in the hMAM RT-qPCR analysis to increase
the sensitivity [4]. The quantification was performed in
a LightCycler 480 (Roche Applied Science) instrument and
the breakpoint cluster region (BCR: GenBank Accession
number NM_004327) was used as a reference gene. KRT19
and TWIST1 were analyzed in duplicates; whereas, hMAM
was analyzed in triplicates.
Relative mRNA quantification
The mean Cq-values of the mRNA markers were normal-
ized against the mean Cq-value of BCR and expressedrelative to a calibrator sample (MDA-MB-361, Ambion
Inc., Austin, TX) using the 2ΔΔCq method [30]. BM samples
from healthy controls were analyzed to determine the high-
est normal BM levels of KRT19 and TWIST1, which were
then used as a cut-off for marker positivity. hMAM was
not detected in the healthy control samples; therefore, any
specific amplification in the patient samples was considered
a positive result. If at least one of the mRNA markers
(KRT19, hMAM, or TWIST1) included in the MM panel
was positive, the patient was considered positive for DTCs.
Statistics
The statistical analyses were performed using SPSS version
21.0 (www.spss.com). A two-sided p-value ≤0.05 was
considered statistically significant. Missing data were
excluded from the analyses. The concordance between
the DTC-statuses assessed by RT-qPCR and ICC was
calculated manually by dividing the number of concord-
ant samples with the total number of analyzed samples,
and by computing Kappa values [31]. The associations
between categorical variables were analyzed by Fishers
exact test for variables with two categories, and by the
Linear-by-Linear Association test for variables with more
than two categories.
Results
We compared mRNA-based and ICC-based methods for
analyzing the presence of DTCs in 313 BM samples
from 271 breast cancer patients. The patients consti-
tuted a subgroup of the SATT-trial and the distribution
of the clinicopathological parameters were similar to
the entire SATT-trial [23]. The clinicopathological pa-
rameters and their relation to patients’ DTC statuses
with both methods are shown in Table 1 for patients
where BM samples were available 8-12 weeks (BM1)
and/or 9 months (BM2) after FEC chemotherapy. No
significant associations were found between clinico-
pathological parameters and BM-status, determined
by ICC or the MM RT-qPCR assay.
The BM DTC-status was positive in 124/313 (40%)
samples by our MM RT-qPCR assay as compared to
23/313 (7%) samples by ICC. Among the 124 MM-positive
samples, 46 (37%) were positive for KRT19, 97 (78%) for
TWIST1, and 3 (2.4%) for hMAM. In addition, TWIST1
was positive in 19 of the 46 KRT19 positive samples. No
significant association was found between the separate
mRNA markers. The relative BM levels of the markers
in the 313 samples from early breast cancer patients are
shown in Figure 1. The comparison between ICC and
the separate mRNA markers/MM panel is summarized
in Table 2. Of the 313 samples analyzed, 190 (61%)
showed concordance between the MM RT-qPCR assay
and ICC (Kappa value 0.045). Only 12 samples were
positive by both methods, but 135 samples were positive
Table 1 Clinicopathological data with ICC- and qPCR-status
All patients (n = 267) ICC qPCR
Number (%) Pos Neg p-value Pos Neg p-value
Age (years) 0.14 0.74
<55 220 (82.4) 21 199 91 129
55-70 43 (16.1) 1 42 19 24
Unknown 4 (1.5)
pT-status 0.524 0.89
pT1a 5 (1.9) 2 3 1 4
pT1b 14 (5.2) 0 14 6 8
pT1c 115 (43.1) 7 108 52 63
pT2 113 (42.3) 10 103 44 69
pT3 14 (5.2) 3 11 7 7
Unknown 6 (2.2)
pN-status 0.14 0.88
pN0 109 (40.8) 7 102 44 65
pN1 118 (44.2) 10 108 52 66
pN2 27 (10.1) 4 23 10 17
pN3 6 (2.2) 1 5 2 4
Unknown 7 (2.6)
Histologic grade 0.80 0.76
Grade I 18 (6.7) 0 18 7 11
Grade II 151 (56.6) 16 135 63 88
Grade III 90 (34.2) 6 84 38 52
Unclassified 4 (1.5) 0 4 2 2
Unknown 4 (1.5)
ER-status 1.00 0.39
Positive 195 (73.0) 16 179 78 117
Negative 67 (25.1) 5 62 31 36
Unknown 5 (1.9)
PgR-status 1.00 0.50
Positive 177 (66.3) 14 163 71 106
Negative 84 (31.5) 7 77 38 46
Unknown 6 (2.2)
HER2-status 1.00 0.59
Positive 37 (13.9) 2 35 17 20
Negative 204 (76.4) 16 188 83 121
Unknown 26 (9.7)
The ICC and RT-qPCR statuses were defined as positive if either BM1 or BM2 was positive. For 238 patients, either BM1 or BM2 was available; whereas, both BM1
and BM2 were available for 29 patients. BM3 and BM4 results were excluded from this analysis because they were only analyzed if ICC BM2 was positive. Four of
the 271 patients had only BM3 or BM4 available and were excluded from the analysis in this table.
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negative by both methods. The concordances between
the individual mRNA markers and ICC were 81% for
KRT19, 67% for TWIST1, and 93% for hMAM.
The DTC detection results at various sampling time
points are shown in Table 3. In BM1, 47.8% of the sampleswere positive for DTCs by the MM RT-qPCR assay as
compared to 33.7% in BM2. The corresponding ICC
results were 7.6% and 5.9%, respectively. Thus, by both
methods, fewer patients had DTCs in BM2 compared
with BM1. For all BM1-4 samples, the number of positives
was much higher, on average 5-fold, by MM RT-qPCR
Figure 1 Relative levels of TWIST1 and KRT19 mRNA in BM samples from 267 early breast cancer patients. The levels were calculated using
the 2ΔΔCq method and normalized by dividing by the highest level in the control samples. The horizontal line represents the highest level in the
control samples with the relative value of one. hMAM is not shown in the plot because no expression was found in the normal control samples.
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have a higher frequency of positive samples because
these samples were only collected from patients with a
positive BM2 sample.
Discussion
This study was undertaken to compare ICC with a MM
RT-qPCR assay for the detection of DTCs in BM after
adjuvant chemotherapy in early breast cancer patients.
Our study revealed a markedly higher frequency of
positive samples by both the MM RT-qPCR assay and
the individual mRNA-assays compared with ICC. Multiple
mRNA markers clearly contributed to a higher number of
positive samples compared to only using single markers.
The relatively high (61%) concordance between ICC andTable 2 Concordance between ICC and mRNA markers
ICC Concordance Kappa
Pos Neg Value
Multimarker Pos 12 112
Neg 11 178 0.61 0.045
KRT19 Pos 4 42
Neg 19 248 0.81 0.020
hMAM Pos 2 1
Neg 21 289 0.93 0.14
TWIST1 Pos 9 88
Neg 14 202 0.67 0.035RT-qPCR is primarily because a large fraction of the
samples were negative by both methods. Accordingly,
the kappa observer agreement value was only 0.04, sug-
gesting that the apparent concordance was primarily
due to chance. In principle, the ICC assay should stain,
among others, KRT19 positive cells. Thus, we expected
better concordance between the ICC and the KRT19
mRNA results. However, only 4 out of 313 samples were
positive by both methods and as many as 42 ICC-negative
samples were positive for KRT19 mRNA. One possible ex-
planation for this is that the KRT19 mRNA assay is more
sensitive than the ICC assay. The 19 ICC-positive samples
that were not detected by the KRT19 mRNA assay might
be explained by detection of KRT19-negative DTCs that
express other keratins detected by the ICC approach.
The low concentration of DTCs in BM samples may
affect reproducibility in both detection methods. Many
samples had levels near the detection limit for KRT19
mRNA; whereas, the ICC-assay was able to detect only a
single cell in the majority of positive samples. It followsTable 3 Distribution of BM1-4 with ICC and qPCR data
BM number Total ICC qPCR Concordant
313 Positive (%) Positive (%) BM results (%)
BM 1 92 7 (7.6) 44 (47.8) (53)
BM 2 187 11 (5.9) 63 (33.7) (66)
BM 3 14 2 (14.3) 10 (71.4) (43)
BM 4 18 3 (16.7) 7 (38.9) (56)
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a roughly 35% risk that a second sample would be a false
negative. Hence, the reproducibility of DTC detection
might be enhanced by analyzing larger sample volumes.
On the other extreme, it was recently shown that screen-
ing a very large volume of peripheral blood by leuka-
pheresis revealed DTCs in 90% of non-metastatic breast
cancer patients [32]. Such high numbers of DTCs does
not correlate with the risk of relapse for this patient
group, and thus implies a dramatic increase in detection
of clinically irrelevant cells.
The hMAM mRNA assay was only positive in a very
small number of samples (3/313); therefore, it might be
of limited value in combination with KRT19 mRNA in
the post-adjuvant treatment setting. Indeed, 2 of the 3
positive hMAM samples were also positive for KRT19
mRNA and by ICC, with convincing DTC-counts of 2
and 46 by ICC. The remaining hMAM positive sample
was TWIST1-positive and KRT19- and ICC-negative.
Thus, it seems that hMAM contributes to the identifica-
tion of a very small subgroup of patients, possibly those
with a very high risk, consistent with our previous report
on hMAM [4,18].
TWIST1 was shown to add prognostic information to
a DTC MM panel described by Tjensvoll et al. [4]. Inter-
estingly, we noted that a substantially higher number of
patients had elevated TWIST1 mRNA levels in our
present study [4]. The clinical follow-up will ultimately
help determine the relevance of this discrepancy. As
TWIST1 is a proposed epithelial-mesenchymal-transition
(EMT)-marker [33], the higher number of positive sam-
ples might indicate that a substantial portion of patients
have DTCs not expressing keratins [34]. The number of
TWIST1 positive samples, however, exceeds the antici-
pated number of clinical relapses. Thus, our assay might
be too sensitive, or the cut-off level needs refinement to
reveal only clinically relevant information. ROC analysis
in relation to clinical outcome data, when available, may
reveal an optimal cut-off value. However, this will require
confirmation in a validation cohort.
The high number of DTC positive samples by the
RT-qPCR approach is in part explained by the high
number of TWIST1 positive samples. In later years,
there has been much focus on mesenchymal markers
to detect cells that have undergone EMT as part of the
metastatic process. This is thought to be a reversible
process in which the cancer cells gain mesenchymal
properties to be able to infiltrate different tissues and
give rise to micro- and ultimately macro metastases [34].
Yu et al. showed that in circulating tumor cells a shift
towards higher expression of EMT-markers is associated
with tumor progression [35]. Thus, we might speculate
whether cells transiently expressing mesenchymal genes,
like TWIST1, comprise the subgroup of DTCs withstem-cell properties and, therefore, the proportion of DTCs
that harbor metastasis-generating abilities [36]. The loss of
epithelial characteristics may imply that these cells are diffi-
cult to detect by most commonly used ICC DTC assays.
The discrepancy between the RT-qPCR based and
the ICC-based DTC detection is not surprising based on
previous studies. Becker et al. found agreement between
ICC (with the A45-B/B3 mAb) and KRT19 mRNA detec-
tion in 73% of the 385 cases, in line with our KRT19 qPCR
results (81% agreement). Although, the results are biased
since the majority of patients were negative by both
methods. In fact, a kappa value of 0.39 can be computed
based on their reported data, confirming this suspicion to
some extent. Moreover, they demonstrated a 35% positive
rate for both ICC and KRT19 mRNA and 49% of the
patients were positive by at least one of the methods. The
time of BM-collection might be an important difference
between their study and the present one. We collected
BM after adjuvant chemotherapy; whereas, Becker et al.
collected the majority of samples prior to surgery and only
a few (n = 63) after surgery and chemotherapy. This may
have contributed to the much lower number of positive
samples based on both ICC and KRT19 mRNA in our
study. Others have reported concordance in the same
range as in our study. Benoy et al. reported concordant
results in 75% of the samples; whereas, Slade et al. found
agreement between the methods in 71% of the samples
[21,22]. Molloy et al. compared a MM RT-qPCR assay
with ICC in a large population of 733 patients and
found both to be significantly predictive of poorer out-
come. However, the RT-qPCR assay was applied to blood
samples (circulating tumor cells) and the ICC to BM sam-
ples (DTCs). Thus, a direct comparison with the current
study is difficult because the samples were collected from
different body regions in addition to being analyzed by
two different methods [37].
A general issue regarding mRNA-based DTC detection
is the background level of epithelial transcripts in white
blood cells. However, comparison with blood samples from
a normal control cohort may compensate for this issue,
allowing threshold values for pathological marker levels in
blood to be established. The latter strategy was utilized in
the current study to minimize the number of false positives
due to such background expression in leukocytes.
Despite clear evidence that DTCs in BM in early
breast cancer patients predict a poor outcome, a better
understanding is needed for these analyses to be imple-
mented in the routine clinical management of patients.
Braun et al. found, in their large pooled analysis of 4703
patients, a significant prognostic value of BM DTC-
status in all patients including the lymph-node nega-
tive subgroup [3]. On the other hand, several smaller
studies, e.g. by Langer et al., did not find any significant
DTC-specific difference in overall and breast cancer
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patients, a result that may be caused by the low number of
patients in the study [3,38]. However, this result emphasizes
that the prognostic value of BM DTC-status might be
strongest in already defined high-risk patients. In the
current analysis, only intermediate/high-risk patients, i.
e. patients with higher-risk node negative or node posi-
tive disease, were included. Thus, this may be a group
where the BM-DTC status may add clinically relevant
prognostic information.
Few studies have investigated the impact of BM-DTCs
after initial therapy. In a pooled analysis, Janni et al. dem-
onstrated that DTCs can be detected several years after
diagnosis [39]. The persistence of BM DTCs after neoad-
juvant treatment was also associated with worse prognosis
in a recent study [40], and our previous results showed re-
duced survival for patients with persistent DTCs, assessed
by our mRNA MM-assay (hMAM, KRT19, and TWIST1),
after surgery [41]. The majority of studies so far have used
ICC for the detection of DTCs in the BM; although, some
studies also used RT-qPCR. The DTC-detection by ICC is
largely based on pan-cytokeratin antibodies, but different
antibody combinations have also been used with varying
results. Effenberger and colleagues found that ICC detec-
tion and prognostic relevance were different for the two
most commonly used pan-cytokeratin antibody combi-
nations (A45-B/B3 (A45) and AE1-AE3 (AE)) [12]. The
AE mAb was more prognostic for the lymph node posi-
tive patients. Accordingly, the AE mAbs were utilized in
the current SATT-trial, consistent with the inclusion of a
higher risk population.
Conclusions
In conclusion, this study is to our knowledge the largest
comparison between ICC- and RT-qPCR-based DTC
detection methods in BM samples collected after adjuvant
chemotherapy in a defined high-risk early breast cancer
population. We detected more positive BM samples with
RT-qPCR assays, based on KRT19, hMAM, and TWIST1
mRNAs, than with ICC. The clinical implications of these
findings, however, await future clinical follow-up. Due
to a potential shift in DTC phenotype, we included the
mesenchymal TWIST1 mRNA marker in an attempt to
detect the subpopulation of DTCs lacking epithelial char-
acteristics. Hopefully, this might help identify additional
patients with clinically relevant DTCs. The current find-
ings support that the different means of detection could
be complementary and that both RT-qPCR and ICC
should be further studied as methods for DTC detection
in early breast cancer patients.
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